Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Didronel PMO

  • Comment

VOL: 101, ISSUE: 27, PAGE NO: 31

Generic and proprietary names

Generic and proprietary names
- Didronel PMO.

- Didronel PMO contains disodium etidronate and calcium carbonate.

- Disodium etidronate decreases the rate of bone turnover and calcium carbonate increases calcium content.

- Bisphosphonate and other drugs affecting bone metabolism.

- Treatment of osteoporosis.

- Prevention of bone loss in postmenopausal women.

- Prevention and treatment of corticosteroid-induced osteoporosis.

- Breastfeeding.

- Pregnancy.

- Hypercalcaemia.

- Hypercalciuria.

- Moderate to severe renal impairment.

- Osteomalacia.

- Renal impairment.

Common side-effects
- Disturbances of the gut such as diarrhoea, constipation, nausea, vomiting or abdominal pain.

Rare side-effects
- Exacerbation of asthma.

- Angioedema.

- Rash or itching.

- Headache.

- Paraesthesia.

- Blood disorders.

- Absorption reduced with calcium salts or calcium-containing products such as milk or other dairy produce.

- May reduce absorption of tetracycline-type antibiotics.

- Vitamin D increases the absorption of calcium.

- If the amount of calcium in the blood becomes too high, it may enhance the effect of digoxin or other cardiac glycosides.

- The two elements of Didronel PMO are taken as a 90-day cyclical regimen. The disodium etidronate tablets are taken for the first 14 days of the treatment cycle, followed by the calcium carbonate tablets for 76 days.

- Calcium tablets are effervescent.

Patient teaching
- This medicine contains the colouring sunset yellow (E110), which can cause an allergic-type reaction.

- The disodium etidronate tablets should be taken with water on an empty stomach.

- The calcium carbonate tablets should be dissolved in water before taking.

- Patients should report any sudden onset of unexplained pain or restricted mobility.

Nursing considerations
- Continuous high-dose use of disodium etidronate is not recommended as it can impair bone mineralisation leading to increased risk of fractures.

- Calcium levels in blood and urine should be monitored in people with kidney disease.

- The therapeutic response should be evaluated.

Nurses should refer to manufacturer's summary of product characteristics and to appropriate local guidelines.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs